--Aecom to serve as reconstruction delivery partner for Ukraine's largest airport » 06:58 ACM --Excelerate Energy price target raised to $20 from $18 at Wells Fargo » 06:26 EE --Bitdeer selloff brings 'compelling buying opportunity,' says H.C. Wainwright » 06:14 BTDR --Bath & Body Works reports Q3 adjusted EPS 48c, consensus 35c » 06:02 BBWI --Citi opens 'upside Catalyst Watch' on Ascendis into FDA feedback » 05:54 ASND --Arcellx price target raised to $62 from $49 at Barclays » 05:49 ACLX --Borr Drilling reports Q3 revenue $191.5M, consensus $187.67M » 05:42 BORR --Janux Therapeutics up 3.5% on insider buying activity disclosed afterhours 18:42 JANX Janux Therapeutics Acting CFO buys $4.99M in common stock » 18:41 --Bill director buys $1.0M in common stock » 18:02 BILL In a regulator --WestRock director Ford buys $424K in company shares 17:37 WRK
The market drops 7% in 3 weeks... you call for a bounce... it climbs 7% in a matter of two weeks, you say watch out below... for a pullback... LMFAO.... #1 forecaster.
Description Bitdeer Technologies Group operates as a technology company for the cryptocurrency mining community. It mines cryptocurrencies for its own account and serve the cryptocurrency mining community by providing cryptocurrency mining solution. The company handles various processes involved in mining, such as miner procurement, transport logistics, mining datacenter design and construction, mining machine management, and daily operations. It has mining datacenters deployed in the United States and Norway. The company is headquartered in Singapore. Bitdeer Technologies Group (BTDR) NasdaqCM - NasdaqCM Real Time Price. 4.2800-0.7200(-14.40%) At close: November 15 04:00PM EST 4.4900+0.21(+4.91%) Pre-Market:
Van I perfectly CALLED THIS RALLY TO THE DAY! and what's even better the sell off before three months in advance-- you simply cannot do better than that-- think about that--> The markets biggest decline and biggest gain both predicted in august... I blew away all the other houses and am ranked #1 on MarketWatch. #1<----- You re asking for the usual overflow of posts that shows how smart I am and unfortunately how wrong you are. Water always finds the path.. into my mouth. Ranked No 1 for a reason...
Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA Ascendis Pharma Wed, November 15, 2023, 8:00 AM EST Watchlist Significant Event | 1d Ascendis Pharma Resubmits NDA For Transcon PTH To The U.S. FDA Ascendis Pharma COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (FDA). The resubmission follows the Type A meeting held with the FDA in late August. “Research has shown that parathyroid hormone (PTH) replacement therapy is the ideal treatment for patients living with the serious impacts of hypoparathyroidism,” said Lynn A. Kohlmeier, M.D., endocrinologist at Spokane Osteoporosis & Endocrinology and Chair, Medical Advisory Board, HypoPARAthyroidism Association. “Seeing significant health and quality-of-life improvements for the majority of patients treated with TransCon PTH in ongoing clinical trials gives me hope that we are closer to achieving a treatment option that goes beyond the limits and risks of conventional therapy with oral calcium and active vitamin D therapy to treat the underlying cause of disease.” “Ascendis Pharma remains committed to providing a treatment option that addresses the underlying disease pathophysiology for patients living with hypoparathyroidism,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “With results from two randomized, double-blind, placebo-controlled clinical trials of TransCon PTH and no new safety concerns identified in follow-up reaching up to four years, we believe TransCon PTH is well-positioned to meet the needs of the hypoparathyroidism community. As no concerns were expressed by the FDA about the clinical data submitted as part of our original NDA, we look forward to working with the agency during its review of our updated manufacturing control strategy for TransCon PTH in the United States.” Ascendis Pharma A/S (ASND) NasdaqGS - NasdaqGS Real Time Price. 92.97-1.73(-1.83%) At close: November 15 04:00PM EST 92.970.00(0.00%) After hours:Nov 15, 05:31PM EST
Now this is what it takes to be #1 When everyone else, yourself included, was bullish af. Nailed it to the day.